The planned interim analysis of CLASSIC showed that adjuvant capecitabine plus oxaliplatin significantly improved disease–free survival, the primary endpoint, compared with observation after D2 gastrectomy. The authors report the 5–year follow–up data from the trial. Adjuvant treatment with capecitabine plus oxaliplatin after D2 gastrectomy should be considered for patients with operable stage II or III gastric cancer.

READ FULL ARTICLE Curated publisher From Mdlinx